Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Mitchells & Butlers shares slide on weaker London sales, costs

(Sharecast News) - Shares in Mitchells & Butlers fell more than 7% on Thursday as news that weaker sales in London and at its premium businesses disappointed investors despite the pub and restaurant group holding annual guidance on the back of a 4.2% rise in like-for-like sales. The Harvester and Toby Carvery owner forecast higher overall cost inflation next fiscal year of around £130m, or 6% of its cost base, but expected to outperform the sector via cost efficiencies.

Chief executive Phil Urban said sales growth in the 51 weeks to September 20 had been broad based, with "strong" like-for-like performances in both food and drink across its portfolio supported by cost management and capital investment.

AJ Bell investment director Russ Mould said: "Fundamentally, Mitchells & Butlers needs to either put up its prices or greatly increase sales volumes so it can achieve economies of scale such as bigger buying power for raw ingredients."

Derren Nathan, head of equity research at Hargreaves Lansdown said the group's diverse brand portfolio, well-invested estate, and focus on efficiency, left it well placed to mitigate cost pressure, while outgrowing the market.

However, he noted that shares in the company have more than doubled over the last three years and the "valuation broadly reflects recent operational improvements".

"With consumer sentiment fragile, and the potential for a further tax grab in the November budget, there's no obvious catalyst for near-term appreciation," he said.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.